Vivek Ra­maswamy's LNP de­liv­ery tech play Genevant scores $600M li­cens­ing deal from Take­da for nu­cle­ic acid ther­a­pies

With mR­NA vac­cines in high de­mand and new RNA ther­a­peu­tics crowd­ing on­to the mar­ket, the de­mand for lipid nanopar­ti­cles has nev­er been high­er. Now, one of se­r­i­al en­tre­pre­neur Vivek Ra­maswamy’s Vant out­fits has scored a big deal with Take­da to de­vel­op LNP-de­liv­ered liv­er drugs.

The Japan­ese drug­mak­er will ear­mark $600 mil­lion for a li­cens­ing deal with Genevant, an LNP de­liv­ery tech out­fit, to de­vel­op nu­cle­ic acid ther­a­pies for liv­er fi­bro­sis, the com­pa­nies said Mon­day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN